HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This study is aimed to evaluate the efficacy and safety of HR20013 versus palonosetron for nausea and vomiting associated with moderate emetic risk anticancer agents